Stockscreener 앱 받기
23.83
0.29%
0.07
시장 영업 전:
23.84
0.01
+0.04%
전일 마감가:
$23.76
열려 있는:
$23.58
하루 거래량:
296.60K
Relative Volume:
1.22
시가총액:
$1.57B
수익:
$282.04M
순이익/손실:
$221.88M
주가수익비율:
7.08
EPS:
3.3658
순현금흐름:
$-449.57M
1주 성능:
-0.63%
1개월 성능:
-10.95%
6개월 성능:
-8.91%
1년 성능:
-36.74%
1일 변동 폭
$23.49
$24.00
1주일 범위
$23.49
$24.04
52주 변동 폭
$23.49
$40.34
갈라파고스 ADR Stock (GLPG) Company Profile
GLPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
23.83 | 1.57B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
갈라파고스 ADR Stock (GLPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-20 | 다운그레이드 | Kepler | Hold → Reduce |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-08-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-19 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-08-06 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-04-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-02-19 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | 개시 | Maxim Group | Buy |
| 2020-10-21 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-08-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-07-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-03-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-18 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | 개시 | BofA/Merrill | Neutral |
| 2019-09-09 | 재개 | Morgan Stanley | Overweight |
| 2019-07-31 | 업그레이드 | UBS | Neutral → Buy |
| 2019-07-29 | 다운그레이드 | Jefferies | Buy → Hold |
모두보기
갈라파고스 ADR 주식(GLPG)의 최신 뉴스
Galapagos To Spin Off Innovative Medicines Business - Forbes
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com
AIM tech shares that broke America - Interactive Investor
Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
GalapagosAll Time High - Seeking Alpha
Galapagos NV ADR (NQ: GLPG - Financial Content
갈라파고스 ADR (GLPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):